SPS
SMMT icon

Susquehanna Portfolio Strategies’s Summit Therapeutics SMMT Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,700
Closed -$234K – 281
2024
Q3 		$234K Hold
10,700
– – 0.02% 303
2024
Q2 		$83.5K Hold
10,700
– – ﹤0.01% 487
2024
Q1 		$44.3K Sell
10,700
-126,371
-92% -$502K ﹤0.01% 775
2023
Q4 		$358K Buy
+137,071
New +$282K 0.01% 829

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Susquehanna Portfolio Strategies's SMMT Position: Q4 2024 in Review

Susquehanna Portfolio Strategies sold out of Summit Therapeutics (SMMT) in Q4 2024, closing a stake of 10,700 shares — an estimated $234K sold.

Susquehanna Portfolio Strategies first reported a position in SMMT in Q4 2023 and held it in 4 quarters. The position peaked at $358K in Q4 2023. 203 funds tracked by Wall St. Rank hold SMMT as of Q4 2024.

  • Susquehanna Portfolio Strategies reported no remaining Summit Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 10,700 Summit Therapeutics shares in Q4 2024, an estimated $234K.
  • Susquehanna Portfolio Strategies first reported a position in Summit Therapeutics in Q4 2023 and held it in 4 quarters.
  • Susquehanna Portfolio Strategies's Summit Therapeutics position peaked at $358K in Q4 2023.
  • 203 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2024.

Based on Susquehanna Portfolio Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.